Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain cancer survivors: can a home program boost your memory?

NCT ID NCT06930846

Symptom relief Sponsor: Dartmouth-Hitchcock Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a home-based program called HOBSCOTCH-CA for brain cancer survivors who struggle with memory and thinking. The program involves weekly virtual sessions with a coach, teaching problem-solving and relaxation techniques. Researchers will compare two groups: one that starts the program right away and another that waits three months. The goal is to see if the program improves quality of life and reduces caregiver burden.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
HOBSCOTCH-CA (a home-based cognitive training and self-management program)
What this could lead to
If it works, this could provide a practical, accessible way for brain cancer survivors to manage memory problems and improve their daily quality of life.
What could go wrong
This is a small, early-stage study (125 participants) with no control group receiving a placebo. The program requires significant time and effort, and results may not apply to all survivors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 125 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

CA Participants will be referred to the study by their providers (Oncologist) who will be made aware of the study and inclusion/exclusion criteria. Inclusion Criteria 2. - 5. and Exclusion Criteria 1. - 3. will be confirmed by referring providers. Participants who learn about the study here and elsewhere will be instructed on how to confirm their eligibility with their provider. Inclusion Criteria for CA Participant: 1. 18 + years 2. Service members, Veterans and civilians with a diagnosis of brain cancer (excluding glioblastoma) 3. Diagnosis of primary brain tumor with expected survival of 2 years or greater (e.g., low-grade glioma, oligodendroglioma, IDH mutant astrocytoma, meningioma) defined as the presence of a primary lesion on neuroimaging (CT or MRI), confirmed by histopathological examination (Note: some patients being treated for meningioma may be treated with radiotherapy without need for initial histopathologic confirmation) 4. Patients undergoing surgical and/or radiation therapy will have completed their treatment at least 3 months prior to being enrolled in trial (Note: patients receiving chemotherapy or other systemic therapy will be included) 5. Stable on all CNS acting medications for one month prior to enrollment 6. Subjective cognitive complaints 7. Literate and proficient in English 8. Internet access for the pre-session and Session 1 of the HOBSCOTCH-CA program; telephone access for sessions 2-8 Exclusion Criteria for CA Participant: 1. Presence of a neurodegenerative disease (e.g., Alzheimer's disease, Parkinson's disease) 2. Acute psychiatric disorder or substance abuse 3. Patients with glioblastoma (GBM) Inclusion Criteria for CA Participant Caregiver: 1. Age 18 + 2. Caregiver to a patient with a confirmed diagnosis of brain cancer/tumor survivor 3. CA Subject has given permission for their caregiver to participate 4. Literate and proficient in English 5. Internet access (for Pre-HOBSCOTCH and Session 1) 6. Telephone access (for Session 8) Exclusion Criteria for CA Participant Caregiver: 1. Significant visual impairment precluding reading or writing 2. No reliable telephone or internet access

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Brain cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

brain cancer brain neoplasm Caregiver Burden cognitive disorder Cognitive Dysfunction IDH-mutant anaplastic astrocytoma low grade glioma low-grade astrocytoma Memory Disorders meningioma oligodendroglioma primary brain neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Brain cancer Brain neoplasms Brain tumor Cognitive dysfunction Low grade astrocytoma Low-grade glioma Memory disorders Memory dysfunction Memory impairment Meningioma Oligodendroglioma Primary brain tumor

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Dartmouth-Health Lebanon

    RECRUITING

    Lebanon, New Hampshire, 03756, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.